Logo IFCT

Select your language

  • FR

IFCT-0803

  • Publications:
  • A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)
  • Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer
  • Phase II study of cetuximab, pemetrexed, cisplatin and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small cell lung cancer (NSCLC): Results of the IFCT-0803 trial
  • Synopsis: IFCT-0803_Synopsis_1.1_050911.pdf

Intergroupe Francophone de Cancérologie Thoracique

Siège social
10 rue de la Grange-Batelière
75009 PARIS

Standard : 01.56.81.10.45
Recherche Clinique : 01.56.81.10.46
Permanence téléphonique du lundi au vendredi : 9h-13h / 14h-17h

Informations

  • Mentions légales
  • Avertissement

Suivez-nous

  • TwitterTwitter
  • LinkedIn
© IFCT 2025 - IFCT_TOUS_DROITS_RESERVES
Contact Devenir membre Espace membre E-lettre Deconnexion